Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask regarding his study on talimogene laherparepvec and ipilimumab in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Advertisement